{"filing":{"accession_number":"0001193125-26-341300","cik":"0000818033","ticker":"HRTX","company_name":"HERON THERAPEUTICS, INC. /DE/","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"hrtx-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312526341300/hrtx-20260810.htm"},"events":[{"id":26390,"run_id":23981,"accession_number":"0001193125-26-341300","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Q2 2026 financial results for the three and six months ended June 30, 2026. The filing explicitly states \"Heron Therapeutics Announces Second Quarter 2026 Financial Results\" and provides detailed net revenue performance by product line, cash position, and operational highlights. The withdrawal of full-year 2026 guidance and discussion of strategic alternatives add material context, but the core disclosure is the quarterly earnings announcement furnished as Exhibit 99.1.","company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27490,"accession_number":"0001193125-26-341300","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for the three and six months ended June 30, 2026. The filing explicitly states \"Heron Therapeutics Announces Second Quarter 2026 Financial Results\" and provides detailed net revenue performance by product line, cash position, and operational highlights. The withdrawal of full-year 2026 guidance and discussion of strategic alternatives add material context, but the core disclosure is the quarterly earnings announcement furnished as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T12:02:11.473839+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27490,"accession_number":"0001193125-26-341300","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for the three and six months ended June 30, 2026. The filing explicitly states \"Heron Therapeutics Announces Second Quarter 2026 Financial Results\" and provides detailed net revenue performance by product line, cash position, and operational highlights. The withdrawal of full-year 2026 guidance and discussion of strategic alternatives add material context, but the core disclosure is the quarterly earnings announcement furnished as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T12:02:11.473839+00:00","company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","filing_date":"2026-08-10"}]}